Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AstraZeneca flop a...

    AstraZeneca flop a fresh blow to cancer immunotherapy combination

    Written by Ruby Khatun Khatun Published On 2018-04-26T09:30:16+05:30  |  Updated On 26 April 2018 9:30 AM IST
    AstraZeneca flop a fresh blow to cancer immunotherapy combination

    LONDON: The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study.


    Adding the company’s experimental drug tremelimumab to its existing product Imfinzi failed to slow disease progression or extend life in patients who had already received at least two previous treatments, the drugmaker said on Tuesday.


    Shares in AstraZeneca fell 1 percent following the news.


    The result of the study, known as ARCTIC, is disappointing but not a huge surprise, since evidence has been building that there may be little value in using a so-called CTLA-4 drug like tremelimumab on top of a PD-L1 such as Imfinzi.




    Indeed, since Imfinzi on its own showed some signs of efficacy, whereas adding tremelimumab did not, analysts believe the second drug might actually offset the efficacy that Imfinzi can offer.


    An ARCTIC sub-study that was not powered for statistical significance found that Imfinzi monotherapy showed a clinically meaningful reduction in the risk of death compared to chemotherapy.


    A year ago, the notion of combining the two medicines was the big hope driving AstraZeneca’s stock price - but that hope was dealt a major blow in July when its main first-line lung cancer trial, called MYSTIC, failed to slow disease progression.


    It is still possible the two-drug combination might succeed in lengthening first-line patients’ lives - a measure called overall survival - but Deutsche Bank analyst Richard Parkes said expectations for this “should now be very low”.


    AstraZeneca is due to report overall survival data from the MYSTIC trial in the second half of this year.



    LUNG CANCER BATTLEGROUND


    Lung cancer is the world’s most common and deadly form of the disease, spurring a battle among companies including AstraZeneca, Merck & Co, Bristol-Myers Squibb, and Roche to develop immune system-boosting treatments.


    The latest findings from a number of studies presented at a medical meeting in Chicago this month suggests that adding chemotherapy to immunotherapy, rather than giving two immunotherapies together, is the most promising approach - a development that is benefiting Merck.


    Luckily, AstraZeneca is finding success elsewhere and the relative importance of double immunotherapy within its portfolio has reduced as the company prepares for a return to sales growth over the next few years.


    Within lung cancer, Imfinzi on its own is also carving out a distinct market in treating patients with inoperable mid-stage disease that has not spread widely around the body.


    AstraZeneca has suffered the industry’s biggest patent cliff since 2012, wiping out more than half of its sales, but it expects sales to grow this year, helped by a number of new medicines.


    Separately on Tuesday, AstraZeneca said it would subscribe for more shares in Circassia by injecting cash into the respiratory drug specialist to take its stake to a maximum of 19.9 percent from 14.2 percent. Shares in Circassia rose 4 percent on the news.





    (Reporting by Ben Hirschler, editing by Louise Heavens)




    ARCTICAstraZenecacancerchemotherapycombinationCTLA-4 drugImfinziimmunotherapyMYSTICPD-L1tremelimumab
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok